Transactions
-
Clearwater Advisers
Adviser to ABF Group’s sale to Warrant Hub, a subsidiary of Tinexta
View more -
Clearwater Advisers
Adviser to Banook’s shareholders on the sale of a majority stake to Motion Equity Partners
View more -
Clearwater Advisers
Adviser to the shareholders of CRP, IMACAM and I-SERIS on their transaction with Parquest
View more -
Clearwater Advisers
Adviser to Kerdonis on the sale of its healthcare division to Univi
View more
Pages
-
Clearwater International has advised on one of France’s largest LBOs to date which saw Sagesse Retraite Santé (SRS), one of France’s leading investors in the health and medico-social sectors, reinvest in DomusVi, alongside Intermediate Capital Group (ICG) and management.
-
The dental market across Europe is also highly fragmented, presenting a significant investment opportunity for both private equity investors and strategic buyers from similar or adjacent healthcare clinical services.
-
As innovator pipelines have deepened and the complexities of developing and manufacturing more recent generations of pharma (including biologics) have increased, the need to simplify manufacturing operations and reduce operating expenditure has led to the emergence of the CDMO industry.
-
Although the market can be traced back to the mid-1900s the sub-sector as we know it today only began to emerge in the 1980s, with the foundation of Quintiles (now IQVIA), Parexel and PPD – all of which are now leading CROs.
-
The international healthcare team has completed nearly 100 healthcare related deals - 20 of these deals have completed within the last 18 months, The dedicated team provide in-depth knowledge and industry experience to every project.
-
The UK dental market remains highly fragmented - in 2018 there were 11,965 registered dental companies/groups and 14,150 dental practices, yet only 12% of these practices were owned by corporate dental bodies indicating that the dental market is ripe for further consolidation.
-
The fragmented UK dental market will generate significant opportunities for investors with increasingly positive market drivers.
-
CROs are constantly expanding their addressable markets by broadening their service offerings, capturing an increasing share of pharma R&D expenditure. Investment in technology and big data will continue to play an important role in the expansion of the CRO sub-sector.
